Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 1
2011 1
2012 1
2014 1
2016 2
2017 2
2018 2
2019 2
2020 3
2021 5
2022 6
2023 1

Text availability

Article attribute

Article type

Publication date

Search Results

24 results

Results by year

Filters applied: . Clear all
Page 1
Reduction in All-Cause Mortality with Fluticasone Furoate/Umeclidinium/Vilanterol in Patients with Chronic Obstructive Pulmonary Disease.
Lipson DA, Crim C, Criner GJ, Day NC, Dransfield MT, Halpin DMG, Han MK, Jones CE, Kilbride S, Lange P, Lomas DA, Lettis S, Manchester P, Martin N, Midwinter D, Morris A, Pascoe SJ, Singh D, Wise RA, Martinez FJ. Lipson DA, et al. Among authors: midwinter d. Am J Respir Crit Care Med. 2020 Jun 15;201(12):1508-1516. doi: 10.1164/rccm.201911-2207OC. Am J Respir Crit Care Med. 2020. PMID: 32162970 Free PMC article. Clinical Trial.
Discordant diagnostic criteria for pneumonia in COPD trials: a review.
Wise RA, Bafadhel M, Crim C, Criner GJ, Day NC, Halpin DMG, Han MK, Lange P, Lipson DA, Martinez FJ, Maselli DJ, Midwinter D, Singh D, Zysman M, Dransfield MT, Russell REK. Wise RA, et al. Among authors: midwinter d. Eur Respir Rev. 2021 Nov 17;30(162):210124. doi: 10.1183/16000617.0124-2021. Print 2021 Dec 31. Eur Respir Rev. 2021. PMID: 34789465 Free PMC article. Review.
Cost-Effectiveness of Single- versus Multiple-Inhaler Triple Therapy in a UK COPD Population: The INTREPID Trial.
Halpin DMG, Kendall R, Shukla S, Martin A, Shah D, Midwinter D, Beeh KM, Kocks JWH, Jones PW, Compton C, Risebrough NA, Ismaila AS. Halpin DMG, et al. Among authors: midwinter d. Int J Chron Obstruct Pulmon Dis. 2022 Oct 25;17:2745-2755. doi: 10.2147/COPD.S370577. eCollection 2022. Int J Chron Obstruct Pulmon Dis. 2022. PMID: 36317185 Free PMC article. Clinical Trial.
Higher COPD Assessment Test Score Associated With Greater Exacerbations Risk: A Post Hoc Analysis of the IMPACT Trial.
Thomashow B, Stiegler M, Criner GJ, Dransfield MT, Halpin DMG, Han MK, Lange P, Martinez FJ, Midwinter D, Singh D, Tabberer M, Wise RA, Lipson DA, Jones P. Thomashow B, et al. Among authors: midwinter d. Chronic Obstr Pulm Dis. 2022 Jan 27;9(1):68-79. doi: 10.15326/jcopdf.2021.0259. Chronic Obstr Pulm Dis. 2022. PMID: 34972260 Free PMC article.
Single-inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol versus dual therapy in current and former smokers with COPD: IMPACT trial post hoc analysis.
Bardsley S, Criner GJ, Halpin DMG, Han MK, Hanania NA, Hill D, Lange P, Lipson DA, Martinez FJ, Midwinter D, Siler TM, Singh D, Wise RA, van Zyl-Smit RN, Berkman N. Bardsley S, et al. Among authors: midwinter d. Respir Med. 2022 Dec;205:107040. doi: 10.1016/j.rmed.2022.107040. Epub 2022 Nov 11. Respir Med. 2022. PMID: 36470149 Free article. Clinical Trial.
24 results